March 22, 2016 – Slone Partners, an executive search firm dedicated to the diagnostics, life science tools, healthcare information technology, and laboratory testing industries, has placed Peter Maimonis Ph.D., as senior vice president and chief science officer of Metamark Genetics.
Dr. Maimonis brings extensive experience in oncology research and development, as well as specific proficiency in oncology biomarkers in the area of prostate cancer. He is a frequent presenter at national and international scientific conferences and has published numerous peer-reviewed articles and abstracts on cancer biomarkers. Dr. Maimonis has held senior-level positions in various areas of research and development at Ciba-Corning, Chiron Diagnostics, Bayer Diagnostics, Decision Biomarkers, and On-Q-ity. He most recently served as vice president of biomarker development at Biothera, working with its novel cancer immunotherapeutic.
“With his accomplished background in the discovery and development of oncology biomarkers, companion diagnostics, and assays, Peter Maimonis will be a true asset to Metamark and our mission to make better patient outcomes possible through access to better information,” said Metamark Genetics CEO Kenneth Weg. “Slone Partners’ knowledge of our industry and our business was essential in finding a high quality individual like Dr. Maimonis for this important role.”
“We have a strong, long-standing partnership with Metamark Genetics, which does incredible work to improve patient outcomes in several disease areas,” said Slone Partners CEO Adam Slone. “As Metamark continues the strategic expansion of its leadership team, we are committed to delivering proven industry leaders that align with the company’s values and who will achieve its business goals.”
Metamark Genetics is a privately held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company’s proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers.
Slone Partners is no stranger to finding leaders for the expanding genetics sector. Over the past several months, the firm has recruited a chief clinical laboratory officer for personalized medicine company Celmatix; a chief medical officer at commercial stage, molecular genetics diagnostic company Signal Genetics; a VP of managed care at medicine company Genomind, and president of North America at cancer detection company Abcodia.
The firm is a nationally recognized senior level recruitment provider that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. It has offices in Boston, New York, Washington, D.C. and San Francisco.
“It’s not clear statistically if demand for CSO’s is changing in terms of volume, but it is clear that expectations in terms of quality are rising substantially,” said Stephen Williams, PhD, a partner at Catalyst Advisors, a global search firm specializing in board, CEO and senior executive assignments for the biopharma industry.
“Companies are looking for that rare combination of high scientific achievement within an area relevant to their business and executive skills,” he said. “As one client put it, ‘The CSO needs to be able to think Nature and to speak Scientific American.” Scientific achievement, he added, is no longer measured in terms of numbers of publications or the thickness of the CV. “It’s really about what they have done or discovered that enables or contributes to new drug discovery and development in a measurable way.”
Investors, said Dr. Williams, “rely on the CSO to drive the science toward value inflections, while company boards rely on them to communicate the science truthfully and understandably to diverse audiences and to be a draw for other scientific talent.”
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media